Dual treatment with atazanavir–ritonavir plus lamivudine versus triple treatment with atazanavir–ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial

Publication | Open Access

DOI Full Paper Access

130

Citations

References

2015

Year

José A. Pérez‐Molina, Rafael Rubio, Antonio Rivero, Juan Pasquau, Ignacio Suárez-Lozano, Melcior Riera, Miriam Estébanez, Jesús Santos, José Sanz, Jesús Troya,

The Lancet Infectious Diseases

Hiv/aids CounsellingTreatment And PreventionNeurovirologyHuman RetrovirusImmunologyAntiviral TherapyDual TreatmentNon-inferiority TrialAntiviral DrugHivMedicineWeek Results